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Excessive human serum albumin (eHSA) impact on anticancer effects is inconsistent.
We explored the outcome of cisplatin (DDP)/etoposide (VP-16) plus eHSA in vivo and
in vitro. C57BL/6 mice with tumor were used to compare the efficacy of DDP/VP-
16 alone and DDP/VP-16+eHSA. Blood albumin was measured to confirm whether
eHSA elevate its level. Western blotting assay were used to measure the expression
of ERCC1/TOP2A in tumor tissues. Cell proliferation, mRNA, and protein expression of
ERCC1/TOP2A were also assayed to compare two groups in A549 cells. Furthermore
we evaluated eHSA impact on cell proliferation in RNAi targeting ERCC1/TOP2A in
A549 cells, respectively. eHSA reduced the anticancer effect of DDP/VP-16 without
altering albumin level, increased protein expression of ERCC1/TOP2A, respectively in
mice. Similarly, eHSA increased mRNA and proteins expression of ERCC1/TOP2A in
A549 cells. In RNAi A549 cells, however, eHSA no longer weakened but enhanced
the anticancer effect of DDP, while no longer altered the effect of VP-16. Our findings
suggested that eHSA weaken the anticancer effect of DDP/VP-16 via up-regulating
ERCC1/TOP2A expression, respectively. Further molecular mechanism studies are
warranted to investigate whether eHSA is not conducive to lung cancer chemotherapy.
Keywords: human serum albumin, cisplatin, etoposide, A549, C57BL/6 mice
INTRODUCTION
Human serum albumin (HSA) has been used in clinical practice for more than 60 years, which is
mainly used for resuscitation and volume expansion in critically ill patients (Liberati et al., 2006).
It is the most abundant protein in plasma and one of the major binders/carriers of drugs that plays
an important role in pharmacokinetic fate (absorption, distribution, metabolism, and excretion)
and pharmacodynamics (Kratz and Beyer, 1998; Leonis et al., 2015; Alam et al., 2016; Ma et al.,
2016; Zaloga et al., 2016). Since the half-life of HSA is about 15–21 days, it cannot be immediately
utilized by the human body, which means that exogenous HSA cannot correct hypoproteinemia
immediately in cancer patients (Sikuler et al., 2000; Talasaz et al., 2012).
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FIGURE 1 | Blood albumin levels of each group at various time points.
(A) Comparison of blood albumin levels between different groups at the end of
different concentrations of HSA treatment. (B) Comparison of blood albumin
levels between different groups at the end of anticancer drugs treatment.
∗P < 0.05, ∗∗P < 0.01.
The administration of HSA has been the subject of intense
debate in China, because HSA is usually abused as tonic for
cancer patients, the older and any other frail people. A few in vitro
studies results of the excessive human serum albumin (eHSA)
supplement impact on chemotherapy is inconsistent (Takahashi
et al., 1980).
Lung cancer is the most common malignant tumors which
is a leading cause of cancer mortality in China (Siegel et al.,
2013), and the routine post-operation chemotherapy is cisplatin
(DDP)/etoposide (VP-16) regimen plus HSA supplement in
China. According to the USA HSA Clinical Application Guide,
the indication of HSA is limited within shock, burns, ARDS,
cardiopulmonary bypass, acute liver failure, and kidney dialysis
occasionally. When HSA level ranges from 15 to 20 g/L, whether
HSA use or not is decided by the specific circumstances of
FIGURE 2 | Body weight of each group at various time points. Time
starting from HSA treatment.
the patient. However, many lung cancer patients who neither
appear hypoproteinemia nor have any indications for HSA
supplement were still prescribed with HSA. eHSA supplement
might cause many adverse reactions including anaphylaxis,
drug fever, kidney damage, heart failure, hemolysis, pulmonary
edema, and other serious incidents (Zhou et al., 2013).
Whether eHSA supplement effect the chemotherapy is worth
exploring.
In this study, we hypothesized that eHSA may impact
anticancer effect in vivo and in vitro. We quantitatively
detected the anticancer effect of DDP/VP-16, mRNA and protein
expression of ERCC1/TOP2A in C57BL/6 mice with tumor and
in human NSCLC A549 cells, as well as in RNAi A549 cells.
Meanwhile, we evaluated the effects of eHSA supplement on
blood albumin level in mice with tumor.
FIGURE 3 | Inoculated tumor weight of each group at the end of
treatment. ∗P < 0.05, ∗∗P < 0.01.
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FIGURE 4 | Volume of inoculated tumor of each group at the end of
treatment. ∗P < 0.05, ∗∗P < 0.01.
FIGURE 5 | Tumor tissue of each group at the end of treatment. (A)
NS+ NS, (B) HSA (L) + NS, (C) HSA (M) + NS, (D) HSA (H) + NS, (E) NS +
DDP, (F) HSA (L) + DDP, (G) HSA (M) + DDP, (H) HSA (H) + DDP, (I) NS +
VP-16, (J) HSA (L) + VP-16, (K) HSA (M) + VP-16, (L) HSA (H) + VP-16.
MATERIALS AND METHODS
Materials
Cisplatin (DDP) was obtained from Qilu Pharmaceuticals, Co.
Ltd (Jinan, China). Etoposide (VP-16) was obtained from
Jiangsu Hengrui Pharmaceutical, Co. Ltd (Jiangsu, China). HSA
(powder) was purchased from Sigma (St. Louis, MO, USA).
HSA was purchased from CSL Behring AG (CH). All materials
for cell culture were purchased from Gibco (Life Technologies,
USA). Cholecystokinin octapeptide (CCK-8) was purchased from
Ruian Biological, Co. (Shanghai, China). Antibodies against
topoisomerase 2α and ERCC1 were obtained from Abcam (USA).
The second antibody goat anti-rabbit IgG were purchased from
Merck. Tubulin and GAPDH anti-rabbit and Beyo ECL Star
were obtained from Beyotime Biological, Co. (Shanghai, China).
SiRNA-mate was purchased from Shanghai Gene Pharma, Co.,
Ltd (Shanghai, China). TliRNaseH Plus was purchased from
Takara Bio Inc (RR420A, Japan). BCA Protein Assay Kit was
purchased from Thermo scientific (Waltham, MA, USA). PVDF
membrane was purchased from Millipore Corp (Bedford, MA,
USA). Chemiluminescence (ECL) detection kit was purchased
from Thermo Fisher (Rockford, IL, USA).
Cell Culture and Animals
Human NSCLC cell line A549 and mice NSCLC cell line LLC
was obtained from Shanghai Institutes of Cell Biology (Shanghai,
China). Cells were cultured in DMEM medium, supplemented
with 10% fetal bovine serum (FBS), 100 µg/mL streptomycin, 100
units/ml penicillin at 5% CO2 at 37◦C.
C57BL/6 male mice of 8-week-old (16–20 g) were purchased
from Academy of Military Medical Sciences (Beijing, China).
Animal (batch number: 1402491) were kept in the Laboratory
Animal Center, East China Normal University, Shanghai (Animal
Experiment License: SYXK 2010-0094). This study was carried
out in accordance with the recommendations of Institutional
Ethics Committee. Normal mice were set as control without any
treatment. All mice inoculated with tumor cells were given 1, 2,
4 g/kg/d of HSA i.v. via tail vein for 3 days respectively, and then
were randomized into 12 groups as follows: Group A: NS + NS,
Group B: HSA (1 g/kg/d) + NS, Group C: HSA (2 g/kg/d) + NS,
Group D: HSA (4 g/kg/d) + NS, Group E: NS + DDP, Group
F: HSA (1 g/kg/d) + DDP, Group G: HSA (2 g/kg/d) + DDP,
Group H: HSA (4 g/kg/d) + DDP, Group I: NS + VP-16, Group
J: HSA (1 g/kg/d) + VP-16, Group K: HSA (2 g/kg/d) + VP-16,
Group L: HSA (4 g/kg/d)+ VP-16. On day 4 the mice were given
2, 10 mg/kg/d of DDP/VP-16 i.p. for 18 days, respectively.
Detection of Blood Albumin Level, Body
Weight, and Tumor Inhibition Rate of
Mice
LLC lung cancer cells (1× 107 cells) suspended in 0.2 mL PBS was
subcutaneously inoculated in the right flank of C57BL/6 mice.
The model was established at day 10 after inoculation. After HSA
administration 3 days later, the blood albumin level was detected
before the chemotherapy initiation (on day 4) and at the end of
treatment (on day 21). Blood albumin level was detected by using
Beckman Coulter (AU5800). During the treatment, tumor length
(L) and width (W) was calibrated using caliper twice a week and
tumor volume was calculated as the formula: V= L×W2/2. After
treatment, tumors were isolated and weighed. The inhibition
rate was calculated as ratio of (1-tumor weight of experiment
group/control group)× 100%.
Western Blotting Assay for ERCC1,
TOP2A Proteins Expression
After being treated with indicated drugs, tumor tissue (groups
A, C, E, G, I, K) were sliced and sonicated while cells were
collected in lysis buffer on ice. The protein was quantified with
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FIGURE 6 | Impact of eHSA on protein expression of ERCC1 and TOP2A in tumor tissues. HSA concentration is 2 g/kg/d, all samples were collected at the
end of treatment.
BCA protein assay kit. Total protein (25 µg) from each sample
were run on SDS-PAGE and electrophoretically blotted onto
PVDF membrane. The blots were blocked with 5% fat-free milk
in Tris-buffered saline-Tween 20 (TBST) at room temperature
for 4 h, followed by incubated with antibody at 4◦C overnight.
All antibodies were diluted with 5% fat-free milk in TBST buffer
according to the instructions. The blots were washed with TBST
buffer three times (10 min each time) at room temperature, and
then labeled with secondary antibody at room temperature for
2 h respectively. Protein bands were detected using an enhanced
chemiluminescence (ECL) detection kit (He et al., 2015).
Cell Viability Assay by CCK-8
Cells (5000 cells per well) were plated into 96-well plates,
then treated with DDP, VP-16, HSA alone or DDP+HSA, VP-
16+HSA for 72 h. Cell viability was assayed using CCK-8
according to the manufacturer’s instructions. The absorbance
of OD at 450 nm was detected and recorded with GloMax-
Muiti+(Promega, E8032, USA).
Determination of mRNA Expression
Cells were seeded into 6-well plates and treated as above for
72 h. Total RNA was extracted with Trizol according to the
protocol (Sangon Biotech, SK1312/BS409, Shanghai, China)
and RNA concentration were measured with NanoDrop ND-
100 Spectrophotometer (Thermo Scientific, Wilmington, DE,
USA). For qRT-PCR, TliRNaseH Plus was used according to
the manufacture’s protocol (Sun et al., 2015). The primers
sequences are as follows: ERCC1, forward 5′-CATCGCCGCAT
CAAGAGA-3′, reverse 5′-TTGGGGTCTCAGGTTGTGTTT-3′;
TOP2A, forward 5′-CAAACTCGATGCCAATGA-3′, reverse
5′-GTCTCTCCCAACCACACCAAG-3′; GAPDH, forward 5′-G
TCTTCACCACCATGGAGAAGG-3′, reverse 5′-GGCAGGTCA
GGTCCACTGA-3′.
RNA Interference (RNAi)
A549 Cells (150000 cells per well) were seeded into 6-well plates
for 24 h, ERCC1/TOP2A were respectively interfered with OPTI-
MEM 500 µL +siRNA-mate 1000 pmol +corresponding siRNA
1000 pmol. Then cells treated with DDP, VP-16, HSA alone or
DDP+HSA, VP-16+HSA combination for 72 h and collected for
Western blotting and qRT-PCR.
A549 cells (5000 cells per well) were seeded into 96-well
plates for 24 h, ERCC1 and TOP2A were respectively interfered
with OPTI-MEM 50 µL+siRNA-mate 100 pmol+ corresponding
FIGURE 7 | Effect of HSA on inhibition rate of DDP and VP-16 in A549 cells and RNAi A549 cells. (A) Effect of HSA on inhibition rate of DDP and VP-16 in
A549 cells. (B) Effect of HSA on inhibition rate of DDP and VP-16 in RNAi A549 cells. Date are mean ± SD, n = 3 means of triplicate measures.
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FIGURE 8 | Effects of HSA on mRNA expression of ERCC1 and TOP2A in A549 cells and RNAi A549 cells. (A,B) The mRNA expression of ERCC1 and
TOP2A from statistical analysis of three independent experiments in A549 cells. (C,D) The mRNA expression of ERCC1 and TOP2A from statistical analysis of three
independent experiments in RNAi A549 cells. ∗P < 0.05, ∗∗P < 0.01.
siRNA 80 pmol. Eight hours later, cells treated with DDP, VP-
16, HSA alone or DDP+HSA, VP-16+HSA combination for 72 h
and collected for CCK-8 test.
The primers of corresponding siRNA are as follows: ERCC1-
homo-294 sense 5′–3′ GCCAAGCCCUUAUUCCGAUTT,
antisense 5′–3′ AUCGGAAUAAGGGCUUGGCTT; TOP2A-
homo-3522 sense 5′–3′ GACCAACCUUCAACUAUCUTT,
antisense 5′–3′ AGAUAGUUGAAGGUUGGUCTT.
Statistical Analysis
Data were expressed as mean ± SD. Statistical comparisons
between the two groups were performed using the Student’s
t-test and the intergroup were performed using the One-way
analysis of variance (ANOVA). All analyses were performed using
the statistical package for the social sciences (SPSS) 19.0, and
(two-tailed) P< 0.05 was considered to be statistically significant.
RESULTS
Impact of eHSA Supplement on Blood
Albumin Level and DDP/VP-16
Anticancer Effects in Mice with Tumor
To evaluate the effects of eHSA supplement on DDP/VP-16
anticancer effects in mice with tumor, we performed in vivo assay
in C57BL/6 mice. Normal mice were set as control without any
treatment. All mice inoculated with tumor cells were given HSA
for 3 days, and then were randomized into 12 groups as follows:
Group A: normal saline (NS)+ NS, Group B: HSA (L) (low dose
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FIGURE 9 | Effects of HSA on protein expression of ERCC1 and TOP2A in A549 cells and RNAi A549 cells. (A) The protein expression of ERCC1, TOP2A
was detected by Western blotting in A549 cells. (B) The protein expression of ERCC1, TOP2A was detected by Western blotting in RNAi A549 cells.
of HSA) +NS, Group C: HSA (M) (medium dose of HSA) +NS,
Group D: HSA (H) (high dose of HSA)+NS, Group E: NS+DDP,
Group F: HSA (L) +DDP, Group G: HSA (M) +DDP, Group H:
HSA (H) +DDP, Group I: NS+VP-16, Group J: HSA (L) +VP-
16, Group K: HSA (M) +VP-16, Group L: HSA (H) +VP-16.
DDP/VP-16 was given respectively for 18 days. Blood albumin
level was detected before the chemotherapy initiation (day 4th)
and at the end of treatment (day 21st).
The results displayed that blood albumin levels were
positively correlated with HSA supplement in mice before the
chemotherapy initiation [HSA (H)>HSA (M)>HSA (L)>NS].
However, at the end of treatment their levels in 12 groups
were almost the same, suggesting that supplemented HSA was
catabolized completely with the time (Figure 1). At the end of
treatment, the body weight of mice in Groups A ∼ D increased
gradually, meanwhile decreased gradually in Groups E ∼ H and
Groups I∼ L. However, the body weight of mice in Group E was
slightly less than that Groups F, G, and H. Similarly, the body
weight of mice in Group I was slightly less than that in Groups J,
K, and L, although no statistically difference existed among these
groups (P > 0.05) (Figure 2).
Furthermore, we observed that the tumor weight in Groups E
and I decreased more than that in Groups F, G, H and Groups
J, K, L, respectively (P < 0.05) (Figure 3). The tumor growth
inhibition rates of DDP treatment Groups E, F, G, H were 44.35,
36.89, 30.92, 29.42%, respectively. The tumor growth inhibition
rates of VP-16 treatment Groups I, J, K, L is 32.41, 28.78, 21.54,
19.83%, respectively. Similarly, the tumor volume in Groups E
and I decreased more than that in Groups F, G, H and Groups J,
K, L, respectively (P < 0.05) (Figure 4). These results suggested
that eHSA supplement weakened the anticancer effects of DDP
and VP-16 in mice with tumor.
Histopathological results displayed that the tumor tissue was
soft with smooth or festering surface in Groups A, B, C, and D.
In Groups E ∼ L, the tumor texture was very hard with a slightly
uneven surface, more bleeding as compared with that in Groups
A∼ D (Figure 5).
Impact of eHSA on Protein Expression
ERCC1 and TOP2A in Tumor Tissue
ERCC1 and TOP2A are prominent targets of DDP and VP-16,
respectively (Verdier-Pinard et al., 2003; Olaussen et al., 2006).
We further investigated whether eHSA weakend the anticancer
effeect via regulating ERCC1 and TOP2A expression in mice. At
the end of treatment, tumor tissue in mice of Groups A, C, E, G,
I, K was isolated and proteins were detected by Western blotting.
We found that eHSA supplement significantly enhanced protein
expression of ERCC1 and TOP2A compared with DDP/VP-16
monotherapy group (Figure 6).
Impact of eHSA Supplement on
DDP/VP-16 Anticancer Effect in A549
Cells and RNAi A549 Cells
To verify eHSA weakening anticancer effect in vitro, we evaluated
the impact of eHSA on cell viability with/without DDP/VP-16
treatment in human NSCLC A549 cells and RNAi A549 cells. We
performed CCK-8 assay by exposure of the cells to 10 µmol/L
DDP/VP-16 and 10/20 µmol/L HSA for 72 h. The results
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showed that eHSA significantly weakened the inhibiting effect of
DDP/VP-16 in A549 cells (Figure 7A). However, in RNAi A549
cells, eHSA no longer weakened but enhanced the inhibiting
effect of DDP alone, meanwhile eHSA no longer altered the
effect of VP-16 alone (Figure 7B). Similarly, eHSA supplement
significantly enhanced the mRNA expression of ERCC1 and
TOP2A compared with the monotherapy group in A549
cells (Figures 8A,B). In ERCC1 and TOP2A RNA interfered
A549 cells, mRNA expression of ERCC1 and TOP2A were
apparently reduced (Figures 8C,D). eHSA supplement enhanced
the protein expression of ERCC1 and TOP2A compared with the
monotherapy group in A549 cells (Figure 9A). In ERCC1 and
TOP2A RNA interfered A549 cells, protein expression of ERCC1
and TOP2A were significantly decreased (Figure 9B). These
results suggested that ERCC1 and TOP2A might be involved in
cell viability in A549 cells.
DISCUSSION
The administration of HSA is a controversial topic in clinical
practice especially in China, whether the use HSA is beneficial
or not is unclear. Although, the indication of HSA is limited
according to the USA HSA Clinical Application Guide, it has
been abused as a tonic both in developed areas and in remote
backward areas in China. It is often inadvisable recommended
for serious diseases such as malignant tumors by family members
(Grootendorst et al., 1988; Finfer et al., 2004; Morris et al., 2014).
In clinical practice HSA is only recommended to use for critical
situation as HSA level is less than 15 g/L. Our preliminary survey
in lung cancer patients displayed that about 30% of patients with
HSA level larger than 35 g/L were still prescribed with HSA
supplement. However, up to now, the impact of eHSA on efficacy
of chemotherapy is not clear.
Takahashi et al. (1980) reported the impact of HSA on
13 anticancer agents in human leukemia cell MOLT-3. Three
outcomes of anti-cancer activity were observed: decreased,
unchanged, and enhanced (Takahashi et al., 1980). Our work
focused on the anticancer effect of DDP, VP-16 in combination
with eHSA in vivo and in vitro. We found that eHSA supplement
reduced the anticancer effect of DDP/VP-16 without altering
blood albumin level as compared with the corresponding
monotherapy group in mice with tumor. Excessive HSA
significantly up-regulated the protein expression of ERCC1
and TOP2A respectively in mice with tumor. In vitro, eHSA
weakened the anticancer effect of DDP/VP-16 in a dose-
dependent manner by up-regulating the protein and mRNA
expression of ERCC1/TOP2A in A549 cells. Remarkably, we
showed that in ERCC1/TOP2A RNAi A549 cells, eHSA no longer
weakened but enhanced the anticancer effect of DDP, while no
longer altered the effect of VP-16, respectively.
The in vivo results demonstrated that eHSA supplement did
not affect the body weight of mice. The blood albumin level was
positively related to the HSA dose on day 4. Interestingly, HSA
levels in 12 groups were almost the same at the end of treatment,
suggesting that supplemented HSA was catabolized completely
with the time (Powell et al., 2013).
ERCC1/TOP2A is resistance gene of DDP/VP-16, respectively
(Verdier-Pinard et al., 2003; Olaussen et al., 2006). Our results
showed that eHSA enhanced mRNA/protein expression of
ERCC1 and TOP2A both in vivo and in vitro. However, in
ERCC1 RNAi and TOP2A RNAi A549 cells, eHSA increased
the effect of DDP while no longer altered the effect of VP-16.
These data suggested that ERCC1 might be one of targets by
which eHSA weakened the anticancer effect of DDP. We suspect
there are another pathway regulate efficacy of DDP which altered
by HSA (Chen et al., 2016). eHSA might weaken anticancer
effect of VP-16 via up-regualting TOP2A exclusively. Based on
these evidences above, we reason that eHSA supplement may
reduce the clinical efficacy of anticancer drugs. Excessive HSA
supplement might not benefit for lung cancer patients with
normal albumin levels (Song et al., 2011).
Different HSA-drug interaction outcomes (Takahashi et al.,
1980) suggested that the impact of HSA supplement (especially
eHSA supplement in China) might be drug-specific, disease-
specific which cannot be generalized (Tang et al., 2011; Punith
and Seetharamappa, 2012; Yousefi et al., 2012; Wu et al.,
2013). It is of importance to individualize HSA use for cancer
patients. Further in vivo experiments and mechanism studies are
warranted to investigate whether eHSA exhibits is not conducive
to therapy of lung cancer patients.
CONCLUSION
In summary, our research about eHSA combination with
DDP/VP-16 in vivo and in vitro showed negative effect
to anticancer drugs, which suggested that eHSA weaken
the anticancer effect of DDP/VP-16 via up-regulating
ERCC1/TOP2A expression, respectively. But further molecular
mechanism studies are warranted to investigate whether eHSA is
not conducive to lung cancer chemotherapy.
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